🇺🇸 FDA
Pipeline program

Itepekimab (SAR440340)

ACT18421

Phase 2 small_molecule active

Quick answer

Itepekimab (SAR440340) for Chronic Rhinosinusitis Without Nasal Polyps is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Chronic Rhinosinusitis Without Nasal Polyps
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials